{
    "clinical_study": {
        "@rank": "139725", 
        "arm_group": {
            "arm_group_label": "SL-401", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a non-randomized, open-label, multi center study.  A cycle of therapy is 5\n      consecutive days every 21 days for 6 or more cycles."
        }, 
        "brief_title": "SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia", 
        "condition": [
            "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", 
            "Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion / Exclusion Criteria to be provided"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113982", 
            "org_study_id": "STML-401-0114"
        }, 
        "intervention": {
            "arm_group_label": "SL-401", 
            "intervention_name": "SL-401", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "overall_contact": {
            "email": "erowinsky@stemline.com", 
            "last_name": "Eric Rowinsky, MD", 
            "phone": "646-203-2311"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary Outcome Measures include Safety and Efficacy", 
            "time_frame": "Please refer to the Study Completion date"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113982"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Stemline Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stemline Therapeutics, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}